Table 1. Clinico-pathological characteristics of the patients in the tumor and control groups.
| Sample | Cancer Type | Gender | Age (mo) | Additional Comments | Confirmatory Study |
|---|---|---|---|---|---|
| 1 | MYCN-amplified HR neuroblastoma | M | 98 | Undifferentiated | ✓ |
| 2 | MYCN-amplified HR neuroblastoma | M | 6 | Undifferentiated | ✓ |
| 3 | LR neuroblastoma | M | 67 | Ganglioneuroblastoma | ✓ |
| 4 | LR neuroblastoma | F | 21 | Differentiating | ✓ |
| 5 | Hepatoblastoma | M | 14 | Mixed fetal and embryonal type histology | ✓ |
| 6 | Hepatoblastoma | M | 85 | Mixed fetal and embryonal type histology | ✓ |
| 7 | Hepatoblastoma | F | 25 | Fetal type histology | |
| 8 | Hepatoblastoma | F | 14 | Fetal type histology | ✓ |
| 9 | Wilms tumor | F | 54 | Biopsy - anaplastic histology | ✓ |
| 10 | Wilms tumor | M | 22 | Biopsy -stromal type histology; WAGR | ✓ |
| 11 | Wilms tumor | F | 12 | Biopsy - mixed type histology | |
| 12 | Wilms tumor | F | 25 | Biopsy - triphasic histology. Failed QC. | |
| 13 | Wilms tumor | M | 41 | Bilateral tumors | |
| 14 | Wilms tumor | F | 16 | Biopsy - stromal type histology | |
| 15 | Wilms tumor | F | 97 | Biopsy - triphasic histology | |
| 16 | Rhabdomyosarcoma | M | 121 | Abdominal | ✓ |
| 17 | Rhabdomyosarcoma | M | 52 | Pancreatic site; jaundiced; embryonal type | |
| 18 | Rhabdomyosarcoma | F | 104 | Nasopharyngeal site; embryonal type | ✓ |
| 19 | Ewings sarcoma | M | 152 | Bone and soft tissue of cervical vertebrae | |
| 20 | Ewings sarcoma | M | 34 | Soft tissue of lumbo-sacral region | |
| 21 | Osteosarcoma | F | 103 | Previous RMS/Li Fraumeni syndrome | |
| 22 | B-cell non-Hodgkin’s lymphoma | M | 176 | Burkitt’s lymphoma | ✓ |
| 23 | B-cell non-Hodgkin’s lymphoma | M | 110 | Burkitt’s lymphoma | ✓ |
| 24 | Hodgkin’s disease | F | 186 | Classical, nodular sclerosing subtype | |
| 25 | Hodgkin’s disease | M | 156 | Classical, nodular sclerosing subtype | ✓ |
| 26 | Hodgkin’s disease | M | 176 | Classical, nodular sclerosing subtype | ✓ |
| 27 | Hodgkin’s disease | F | 159 | Classical, nodular sclerosing subtype | |
| 28 | Hodgkin’s disease | F | 172 | Classical, nodular sclerosing subtype | |
| 29 | Pleuropulmonary blastoma | F | 133 | Germline DICER1 mutation | |
| 30 | Central nervous system glioma | M | 53 | Pilocytic astrocytoma WHO 2007 grade I | ✓ |
| 31 | Central nervous system glioma | F | 68 | Pilocytic astrocytoma WHO 2007 grade I | |
| 32 | Central nervous system glioma | M | 172 | Gliomatosis cerebri, WHO 2007 grade III | |
| 33 | Central nervous system glioma | F | 17 | Oligodendroglioma WHO 2007 grade II | |
| 34 | Central nervous system glioma | M | 59 | Pilocytic astrocytoma WHO 2007 grade I | ✓ |
| 35 | MYCN-amplified HR neuroblastoma | F | 17 | Undifferentiated; abdominal | ✓ |
| 36 | MYCN-amplified HR neuroblastoma | M | 32 | Undifferentiated; abdominal | ✓ |
| 37 | LR neuroblastoma | M | 5 | Poorly differentiated | ✓ |
| 38 | LR neuroblastoma | M | 3 | Poorly differentiated | ✓ |
| 39 | Control | F | 38 | N/A | |
| 40 | Control | M | 159 | N/A | |
| 41 | Control | F | 34 | N/A | ✓ |
| 42 | Control | F | 142 | N/A | ✓ |
| 43 | Control | F | 129 | N/A | |
| 44 | Control | M | 23 | N/A | |
| 45 | Control | F | 21 | N/A | |
| 46 | Control | M | 57 | N/A | |
| 47 | Control | M | 34 | N/A | |
| 48 | Control | F | 38 | N/A | ✓ |
| 49 | Control | M | 134 | N/A | |
| 50 | Control | M | 48 | N/A | |
| 51 | Control | M | 74 | N/A | |
| 52 | Control | F | 140 | N/A | |
| 53 | Control | M | 181 | N/A | |
| 54 | Control | M | 29 | N/A | |
| 55 | Control | M | 26 | N/A | |
| 56 | Control | F | 50 | N/A | |
| 57 | Control | M | 36 | N/A | ✓ |
| 58 | Control | F | 86 | N/A |
Abbreviations: MYCN-NB = MYCN-amplified high-risk neuroblastoma; NB = non-MYCN-amplified low-risk neuroblastoma; HB = hepatoblastoma; WT = Wilms tumor; RMS = rhabdomyosarcoma; ES = Ewing’s sarcoma; OS = osteosarcoma; B-NHL = B-cell non-Hodgkin’s lymphoma; HD = Hodgkin’s disease; PPB = pleuropulmonary blastoma; GL = Central nervous system glioma; C = control samples. Samples 35-38 were independent samples used for the technical confirmation study only.